A5050563063- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Cancer Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Scoliosis diagnosis and treatment
- Renal and related cancers
- Spinal Fractures and Fixation Techniques
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Inflammatory Bowel Disease
- Ferroptosis and cancer prognosis
- COVID-19 and healthcare impacts
- Spine and Intervertebral Disc Pathology
- Multiple and Secondary Primary Cancers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Surgical Treatments
- Economic and Financial Impacts of Cancer
- Cutaneous Melanoma Detection and Management
- Viral-associated cancers and disorders
- COVID-19 Clinical Research Studies
- Hip disorders and treatments
- Venous Thromboembolism Diagnosis and Management
- Single-cell and spatial transcriptomics
Dana-Farber Cancer Institute
2022-2025
Harvard University
2022-2025
Yale Cancer Center
2023-2025
Molecular Oncology (United States)
2024-2025
Yale University
2024-2025
Boston University
2025
Yale New Haven Hospital
2025
Saint Joseph University
2017-2023
Kidney Centre
2023
Cleveland Clinic
2023
Abstract Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability identify the transcriptional programs that govern phenotypes and their dynamic changes during course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling from 1 ml patient plasma. Using an immunoprecipitation-based approach targeting histone modifications methylation, measured 1,268 profiles...
Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population clinical trials. We analyzed data for patients or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total 389/4799 (8.1%) had on initiation systemic therapy. First-line immuno-oncology (IO)-based combination therapy was associated longer median overall survival (OS; 32.7 mo, 95% confidence...
Immune checkpoint inhibitors have significantly transformed the treatment paradigm for metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving remarkable deep durable responses. However, given multiple ICI-containing, standard-of-care regimens approved RCC, identifying biomarkers that predict therapeutic response resistance is of critical importance. Although tumor-intrinsic features such as pathological characteristics, genomic alterations, transcriptional...
Introduction Adult spinal deformity (ASD) is classically evaluated by health-related quality of life (HRQoL) questionnaires and static radiographic spino-pelvic global alignment parameters. Recently, 3D movement analysis (3DMA) was used for functional assessment ASD to objectively quantify patient's independence during daily activities. The aim this study determine the role both assessments in prediction HRQoL outcomes using machine learning methods. Methods patients controls underwent...
Renal cell carcinoma (RCC) of variant histology comprises approximately 20% kidney cancer diagnoses, yet the optimal therapy for these patients and factors that impact immunotherapy response remain largely unknown. To better understand determinants in this population, we characterized blood- tissue-based immune markers with RCC, or any RCC sarcomatoid differentiation, enrolled a phase II clinical trial atezolizumab bevacizumab. Baseline circulating (plasma) inflammatory cytokines were highly...
594 Background: Kidney injury molecule-1 (KIM-1) is a circulating biomarker for renal cell carcinoma. The JAVELIN Renal 101 trial established avelumab and axitinib as standard treatment regimen advanced carcinoma (aRCC). In this post-hoc analysis, we evaluated whether baseline plasma KIM-1 change on are associated with outcomes in 101. Methods: Patients aRCC were randomized to plus (Av/Ax) or sunitinib (Sun), previously described. was measured at (C1D1) C3D1 using Luminex microbead-based...
505 Background: The IMDC model has been effectively used to predict patients’ (pts) outcomes with mRCC, significantly guiding treatment decisions in the era of immune checkpoint inhibitors (ICIs) that have improved survival. In this study, we aim characterize clinical between patients classified as low (L, score 0) vs. low-intermediate (L/I, 1) categories. Methods: Data pts mRCC receiving first-line (1L) ICI-based therapies scores 0 or 1 was collected from IMDC. Pts were further subdivided...
509 Background: Comorbidities pose a challenge in the treatment of patients with cancer and present barrier to inclusion clinical trials. While effect comorbidities on efficacy immunotherapy (IO) has been studied various malignancies, it remains unclear metastatic renal cell carcinoma (mRCC) treated IO-based combinations. Methods: Data from mRCC receiving combinations (IO+IO or IO+anti-vascular endothelial growth factor (VEGF)) as first-line were collected Dana-Farber Cancer Institute Tom...
253 Background: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of that can arise after androgen blockade. Early detection NEPC has prognostic and therapeutic implications but remains challenging. (NE) transformation spatially heterogeneous, with co-existing NE adenocarcinoma (AD) components across a patient's disease burden, leading to underdiagnosis using tumor biopsy. Moreover, treatment response assessment cross-sectional imaging cannot distinguish changes in AD...
582 Background: Kidney injury molecule-1 (KIM-1) is overexpressed in clear cell and papillary renal carcinoma (RCC) proximal tubular kidney injury. While circulating KIM-1 a minimally invasive biomarker for RCC, it unknown whether disease, common comorbidity among RCC patients, impacts the association of with outcomes. We evaluated between outcomes metastatic after adjustment multiple biomarkers using plasma proteomics. Methods: Plasma samples from patients were obtained prior to 1 st line...
583 Background: ChRCC is a rare form of kidney cancer that has shown limited response to immune checkpoint inhibitors currently used as the standard-of-care for other RCC histologies. mTOR inhibition therapeutic strategy advanced ChRCC, but mechanistic basis remains poorly understood. We investigated clinical responses in patients with and explored underlying mechanism at single-cell resolution. Methods: Clinical data from International Metastatic Database Consortium (IMDC) was evaluate...
571 Background: Immune checkpoint inhibitors (ICI) have led to remarkable, long-lasting responses in a subset of patients with metastatic renal cell carcinoma (RCC). However, the molecular mechanisms driving these exceptional (ER) are not fully characterized. We previously observed that high tertiary lymphoid structure (TLS) signature is associated ER. Here, we explore metabolic determinants may influence ER treated ICI and VEGF inhibitors. Methods: analyzed genomic transcriptomic data from...
562 Background: ICI-based therapies are the cornerstone of treatment for advanced RCC. While many studies have focused on tumor-based biomarkers, circulating factors play an important role in therapeutic response. This study utilized a high dimensional proteomic platform to investigate plasma proteins from RCC patients undergoing identify potential biomarkers associated with outcomes. Methods: A total 43 samples (n = 40 clear cell; n 3 non-clear cell) were collected 33 patients, 16 paired...
494 Background: Immuno-oncology (IO)-based combination therapy with or without anti-vascular endothelial growth factor (VE) has become a standard of care for mnccRCC. However, real-world evidence on the effectiveness contemporary therapies over traditional targeted against mnccRCC is limited. Methods: Using IMDC, patients were classified into five subgroups based 1L therapies: IOIO, IOVE, CABO, SUN/PAZ, and mammalian target rapamycin (mTOR). Baseline patient characteristics, clinician...
Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated poor survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major barriers improving outcomes for sRCC are the limited understanding of its gene regulatory programs low diagnostic yield tumor biopsies due spatial heterogeneity. Herein, we characterized epigenomic landscape by profiling 107 libraries from tissue plasma samples 50 patients RCC healthy volunteers. By histone modifications DNA...
PURPOSE International medical graduates (IMGs) are an essential component of the oncology workforce in United States, comprising a third all practicing oncologists and almost half hematology/oncology fellows. In this article, we discuss contributions IMGs US workforce, review unique challenges faced by IMGs, propose potential solutions to overcome these challenges. METHODS ASCO's IMG Community Practice was established with mission connect, mentor, guide, raise awareness, interested pursuing...
The management of renal cell carcinoma (RCC) has advanced significantly in the past two decades. Many promising functional imaging modalities such as radiolabeled tracer targeting carbonic anhydrase IX and prostate-specific membrane antigen are under development to detect primary kidney tumors, stage systemic disease, assess treatment response RCC. Immune checkpoint inhibitors PD-1 cytotoxic T-cell lymphocyte-4 have changed paradigm Trials investigating novel mechanisms LAG-3 immune...
4538 Background: Lenvatinib is a tyrosine kinase inhibitor (TKI) that targets both vascular endothelial growth factor (VEGF) receptor and fibroblast receptor. It has demonstrated efficacy in the upfront refractory disease settings. However, there lack of data surrounding TKIs post-lenvatinib exposure. In this study, we investigate activity therapies pts with aRCC. Methods: We conducted retrospective analysis utilizing International Metastatic Database Consortium (IMDC). Pts having received...